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Abstract
Background: Although in vitro and in vivo laboratory studies have suggested that benzalkonium chloride (BAK) in
topical ophthalmic solutions may be detrimental to corneal epithelial cells, multiple short- and long-term clinical
studies have provided evidence supporting the safety of BAK. Despite the conflicting evidence, BAK is the most
commonly used preservative in ophthalmic products largely due to its proven antimicrobial efficacy. This study was
designed to characterize the antimicrobial performance of two commonly used topical ocular hypotensive agents
that employ different preservative systems: latanoprost 0.005% with 0.02% BAK and travoprost 0.004% with sofZia, a
proprietary ionic buffer system.
Methods: Each product was tested for antimicrobial effectiveness by European Pharmacopoeia A (EP-A) standards,
the most stringent standards of the three major compendia, which specify two early sampling time points (6 and
24 hours) not required by the United States Pharmacopeia or Japanese Pharmacopoeia. Aliquots were inoculated
with between 10
5 and 10
6 colony-forming units of the test organisms: Staphylococcus aureus, Pseudomonas
aeruginosa, Escherichia coli, Candida albicans and Aspergillus brasiliensis. Sampling and enumeration were conducted
at protocol-defined time points through 28 days.
Results: BAK-containing latanoprost met EP-A criteria by immediately reducing all bacterial challenge organisms to
the test sensitivity and fungal challenges within the first six hours while the preservative activity of travoprost with
sofZia did not. Complete bacterial reduction by travoprost with sofZia was not shown until seven days into the
test, and fungal reduction never exceeded the requisite 2 logs during the 28-day test. Travoprost with sofZia also
did not meet EP-B criteria due to its limited effectiveness against Staphylococcus aureus. Both products satisfied
United States and Japanese pharmacopoeial criteria.
Conclusions: Latanoprost with 0.02% BAK exhibited more effective microbial protection than travoprost with
sofZia using rates of microbial reduction, time to no recovery for all challenges and evaluation against EP-A criteria
as measures. The rapid and complete reduction of all microbial challenges demonstrates that antimicrobial activity
of latanoprost with 0.02% BAK exceeds that of travoprost with sofZia preservative system in these products and
provides a more protective environment in the event of contamination and subsequent exposure to
microorganisms during use.
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Adequate preservation is of paramount importance in
ophthalmic solutions packaged in multidose containers
to minimize the risk of infection associated with inad-
vertent microbial contamination. Yet, even when pre-
served with benzalkonium chloride (BAK), microbial
contamination has been found to be present in 28% to
29% of in-use containers [1,2], with a significantly
greater frequency in those used for more than 8 weeks
[2]. This contamination translated into a high concor-
dance of the same organisms cultured from the con-
junctiva [1,2], especially in patients with ocular surface
disease (OSD) [1]; one-third of patients reported having
touched their eyes during medication installation [1].
Coagulase-negative Staphylococcus, Staphylococcus aur-
eus and a variety of gram-negative bacteria that are not
usual conjunctival flora were among the potentially
pathogenic organisms identified [1,2]. In more recent
studies using video recordings to evaluate the perfor-
mance of patients with ocular hypertension or glau-
coma, supported by Alcon, only a third of patients were
actually successful at instilling a single drop of medica-
tion without touching the eye or ocular adnexae [3,4].
A quaternary ammonium compound with bacterio-
static and bacteriocidal properties, BAK has been used
to preserve ophthalmic medications since the late 1940s
[5]. Today, more than 70% of ophthalmic medications
available in multidose containers, including topical ocu-
lar hypotensive agents, contain BAK in concentrations
typically ranging from 0.004% to 0.02% [6]. An alterna-
tive preservative system, sofZia
®, an ionic buffer that
contains borate, sorbitol, propylene glycol and zinc [7],
recently has been developed and approved by the U.S.
Food and Drug Administration. SofZia has been used
since as an alternative to BAK (0.015%) in Travatan Z
®
(Alcon, Inc. Fort Worth, Texas, USA), another available
formulation of travoprost ophthalmic solution.
The present study characterizes and compares the
antimicrobial performance of these preservatives in the
commonly used topical ocular hypotensive agents lata-
noprost 0.005% with 0.02% BAK [8] and travoprost
0.004% with sofZia [7]. Both products are approved for
sale in the United States [7,8] and Japan [9], and latano-
prost ophthalmic solution is approved in the European
Union (EU). While travoprost ophthalmic solution with
0.014% BAK is approved in the EU [10], travoprost with
sofZia is not.
Standards for preservative effectiveness are set forth in
the European Pharmacopoeia (EP) [11], including both
EP-A and EP-B criteria for antimicrobial activity, and in
the United States Pharmacopeia (USP) [12] and the
Japanese Pharmacopoeia (JP) [13]. These recognized
standards were used as comparative assessment mea-
sures in this work. The EP (edition 6.6, chapter 5.1.3)
[11] test for efficacy of antimicrobial preservation of
ophthalmic preparations using the EP-A evaluation cri-
teria for antimicrobial activity is widely recognized for
evaluating preservative effectiveness in pharmaceutical
products marketed in EP member states. The EP-A eva-
luation demands two early sampling time points (6 and
24 hours) not required by either the USP (chapter 51)
[12] or the JP (general information chapter 19) [13],
therefore representing the most stringent of the three
major compendia. The EP-B criteria are reserved for jus-
tified cases where criteria A cannot be attained, such as
products that would be of “increased risk of adverse
events.”
Methods
The antimicrobial effectiveness testing was conducted at
Lancaster Laboratories (Lancaster, Pennsylvania, USA),
an independent laboratory, according to the EP-A stan-
dards (EP-A; Tables 1 and 2[11]). Additional measure-
ment time points and microorganisms were included to
allow for the evaluation of results against EP evaluation
criteria B (EP-B; Table 2) and the USP [12] and the JP
[13] standards (Table 1). Latanoprost ophthalmic solu-
tion 0.005% with 0.02% BAK or travoprost 0.004%
ophthalmic solution with sofZia were tested against the
following bacteria and fungi: Staphylococcus aureus
(ATCC 6538), Pseudomonas aeruginosa (ATCC 9027),
Escherichia coli (ATCC 8739), Candida albicans (ATCC
10231) and Aspergillus brasiliensis (a subspecies of
Aspergillus niger; ATCC 16404). These organisms were
selected based on EP [11] and USP [12] test protocols.
According to the standard methodology, the bulk dilu-
tion was split into 10 mL aliquots, which were
Table 1 Microorganisms and postinoculation time points
tested in this protocol and required by EP-A and USP/JP
[11-13]
Microorganisms included in all tests
Pseudomonas aeruginosa
Staphylococcus aureus
Candida albicans
Aspergillus brasiliensis
Escherichia coli*
Time points Protocol EP-A USP/JP
0 hour T T T
6 hours T T N
24 hours T T N
7 days T T (mold only) T
14 days T N T
28 days T T T
JP: Japanese Pharmacopoeia; N: not included in test; T: included in test; USP:
United States Pharmacopeia.
*By European Pharmacopoeia-A (EP-A) standards, only required for oral
products [11].
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5 and 10
6 colony-forming
units (CFU)/mL of each organism (1 organism per ali-
quot) and stored at 20°C to 25°C. Sampling and enu-
meration of the inoculated samples were done at
protocol-defined time points through 28 days (Table 1)
[11]. One mL aliquots were serially diluted in typtone-
azolectin-Tween broth and plated in duplicate on tryp-
tic-soy agar (for bacteria) or Sabouraud dextrose agar
(for fungi). Plates were incubated at 30°C to 35°C for ≥3
days for bacteria and 20°C to 25°C for ≥5 days for fungi.
Raw data counts were converted to log10 values and the
reduction from inoculum values was calculated for eva-
luation against compendial requirements. Since the sam-
ples were diluted at least 1:10 at the time of testing, 10
CFU (or 1.0 log reduction) is the lowest sensitivity
allowed by the test.
The recovery methods of the enumeration procedures
were qualified by comparing the recovery of representa-
tive microorganisms (at a low concentration of ≤100
CFU) from the test article to the recovery from positive
controls. At 1:10, all bacteria and fungi had a recovery
rate of ≥95% (1:10 dilution) and ≥87% (1:100 dilution),
respectively, which is within the 70% to 200% range
demonstrating suitability of the recovery method (data
not shown).
The primary endpoints were the differences between
latanoprost and travoprost ophthalmic solutions in their
alignment with the EP-A criteria A, the time to “no
recovery” (report of <10 CFU or <1.0 log) for each
organism/product combination and the recovered
organism counts at 6 and 24 hours as defined in EP
standards.
Results
Latanoprost ophthalmic solution 0.005% with 0.02% BAK
exceeded EP-A criteria with reductions of all bacterial
challenge microorganisms (≥4 . 7l o ga t0h o u r s )a n da l l
fungal challenge microorganisms (≥4 . 4l o ga t6h o u r s )
(Table 3). These results exceeded the requisite 2 log
reductions for bacteria at 6 hours and 2 log reductions for
fungi at 7 days. Travoprost with sofZia did not meet the
EP-A criteria, demonstrating a mean reduction of only 0.5
log (range: 0.1, 1.5) in bacterial counts at 6 hours. At 24
hours, the mean bacterial reduction for travoprost was 1.1
log (range: 0.1, 2.8); reductions ≥4.7 log did not occur
until day 7. The fungal counts never exceeded the requi-
site reductions (2 logs at 7 days) for the duration of the
28-day test (Table 3; Figures 1A and 1B).
Since travoprost did not meet EP-A criteria, the
results were evaluated against EP-B criteria, which
require reductions in bacterial counts of 1 and 3 logs at
24 hours and 7 days, respectively, with no increase at 28
days, and a 1 log reduction in fungal counts at 14 days,
with no increase at 28 days. These less stringent criteria
are reserved for products for which suitable justification
exists for not meeting EP-A criteria, such as an
increased risk of adverse reactions [11]. When evaluated
against EP-B criteria (Table 2), travoprost still did not
satisfy EP requirements due to its limited effectiveness
against Staphylococcus aureus at 24 hours (Table 3).
There was the required 1 and 3 log reductions for Pseu-
domonas aeruginosa and Escherichia coli at 24 hours
Table 2 Parenteral and ophthalmic preparation European
Pharmacopoeia criteria A and B (With permission from
the European Pharmacopoeia [11])
Log reduction
6 hours 24 hours 7 days 14 days 28 days
Bacteria A 2 3 - - NR
B- 1 3 - N I
Fungi A - - 2 - NI
B- - - 1 N I
NI: no increase; NR: no recovery.
Table 3 Microbial reduction (log10 CFU/mL) by time point
Sample Microorganism Inoculum 0 hours 6 hours 24 hours 7 days 14 days 28 days
Latanoprost 0.005% (Lot No: LA54019) S. aureus 5.8 > 4.8 > 4.8 > 4.8 > 4.8 > 4.8 > 4.8
P. aeruginosa 5.7 4.7 > 4.7 > 4.7 > 4.7 > 4.7 > 4.7
E. coli 6.0 > 5.0 > 5.0 > 5.0 > 5.0 > 5.0 > 5.0
C. albicans 5.7 0.9 > 4.7 > 4.7 > 4.7 > 4.7 > 4.7
A. brasiliensis 5.4 0.1 > 4.4 > 4.7 > 4.4 > 4.4 > 4.4
Travoprost 0.004% (Lot No: 158568F) S. aureus 5.8 0 0.1 0.2 > 4.8 > 4.8 > 4.8
P. aeruginosa 5.7 0.1 0.8 1.7 > 4.7 > 4.7 > 4.7
E. coli 6.0 0.3 1.5 2.8 > 5.0 > 5.0 > 5.0
C. albicans 5.7 0.1 0.2 0.1 0.6 1.0 1.8
A. brasiliensis 5.4 0.1 0.2 0.9 1.7 1.9 1.8
CFU: colony-forming unit.
Latanoprost ophthalmic solution 0.005% contains 0.02% benzalkonium chloride and travoprost ophthalmic solution 0.004% contains sofZia as preservatives.
Shading indicates results not meeting European Pharmacopoeia-A (EP-A) requirements [11] (note that while testing of E. coli is required only for non-oral
products in the EP, this would be considered a failing result).
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Page 3 of 6and 7 days, respectively. However, while travoprost mar-
ginally satisfied EP-B criteria for fungi at 14 days (1.0
and 1.9 log reductions for Candida albicans and Asper-
gillis brasiliensis, respectively), reductions were far less
than those achieved at 6 hours by latanoprost with
0.02% BAK.
Discussion
When compared with the compendial requirements
[11], BAK-containing latanoprost exceeded the EP-A
criteria at all time points [11]. Travoprost with sofZia,
however, while meeting USP standards [6,14], did not
meet the EP-A criteria for either bacteria or fungi, exhi-
biting only modest reductions at 6 and 24 hours, nor
did it meet EP-B criteria due to its limited effectiveness
against Staphylococcus aureus. Staphylococcus infections
are frequently associated with both primary and recur-
rent bleb infections following trabeculectomy [15] and
endophthalmitis subsequent to postoperative procedures
such as lens replacement [16]. Pseudomonas aeruginosa
is also a common cause of endophthalmitis, occurring
postoperatively or subsequent to corneal ulcers, and is
often associated with poor visual outcomes [17].
The early time points, which assess the rate of kill of the
challenge organisms, revealed the most significant differ-
ences between the two preservative systems. Latanoprost
with 0.02% BAK exhibited complete reduction of a large
microbial insult (bacterial and fungal) within the first 6
hours of exposure while travoprost with sofZia showed
only modest reductions. These results are especially
important as the early time points simulate microbial con-
tamination that may occur upon use and be present over
the next 24 hours after use. In addition, the fungal/yeast
challenge never reached a point of “no recovery” in the
travoprost samples during the 28-day test.
Benzalkonium chloride also has been shown to be
more effective than other preservatives when measured
against the EP-A criteria [11]. When artificial tears con-
taining BAK (0.01%)/ethylenediaminetetraacetic acid
(EDTA; 0.05%), chlorobutanol (0.5%), stabilized oxy-
chloro complex (50 parts per million), sodium silver
chloride complex (0.001%) or methyl-, ethyl - and pro-
pylparaben (undeclared concentration) were compared
[18], the product containing BAK/EDTA alone satisfied
the criteria for all test microorganisms. The majority of
products failed the criteria for one or more bacteria,
notably with the 6- and 24-hour samples. An agar diffu-
sion test also was performed, with only the BAK/EDTA
sample showing a zone of inhibition; the effect was
s h o w nt ob ed u et oB A Ko n l ys i n c eo t h e rp r o d u c t s
without EDTA gave similar results [18].
Recent studies in which patients were videotaped to
assess their success at instillation of topical ocular hypo-
tensive medications highlight the concerns about bottle
contamination [3,4]. In the first of these studies, 92.8% of
patients with a diagnosis of glaucoma or ocular hyperten-
sion who used 1 or more glaucoma medications for at
least 6 months reported no problems administering their
eye medications; yet, less than a third of patients were
successful at instilling a single drop with touching the
bottle to the eye [3]. In a subsequent study in patients
with visual impairment or moderate to severe visual field
loss, only 39% were able to instill a single drop without
touching the eye; age (<70 vs ≥70 years) was found to be
a significant predictor for less successful instillation [4].
These studies demonstrate that bottle contamination is a
more important issue than previously believed.
There has been an ongoing controversy about the
contributions of BAK-containing ophthalmic solutions
to ocular toxicity, particularly using in vitro studies and
rabbit models, many with exaggerated-use protocols (for
reviews, see Kaur et al [6] and Furrer et al [19]). The
relevance of these studies to the clinical setting is not
well established given the various methodologies, mod-
els, exposure times and concentrations. Several recent
studies, all sponsored by Alcon, have compared travo-
prost to latanoprost or bimatoprost with respect to
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Figure 1 Reduction in microorganism counts over 28 days with
(A) latanoprost with benzalkonium chloride (BAK) and (B)
travoprost with sofZia. CFU: colony-forming unit; Inoc:
inoculation. For ease of graphing <1.0 log was plotted as “0”.
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Page 4 of 6ocular tolerability in glaucoma patients [20-23]. In the
first of these studies, patients (n = 691) who required
alternate therapy due to tolerability issues were switched
from either latanoprost or bimatoprost to travoprost
with sofZia [20]. While there was no significant
difference in the reported OSD index (OSDI) scores
between patients who were classified as normal at base-
line (n = 456), patients who were symptomatic at base-
line (n = 235) reported significant improvements in
their scores 3 months after switching to travoprost.
However, as the authors indicated, the study design
(nonrandomized, nonmasked) was limited so that expec-
tation of improvement may have resulted in patients
subjectively reporting a more favorable outcome.
In other studies involving patients with preexisting
OSD, tolerability findings have been inconsistent. In one
double-blind study, patients who were receiving latano-
prost and reported ocular dryness and irritation (n = 33)
were randomized to receive latanoprost in one eye and
travoprost with sofZia in the other eye; eyes were
a s s e s s e db yas i n g l ee x a m i n e re v e r y3t o4w e e k sf o r3
months, and patients completed an OSDI survey [23].
Significant increases in corneal staining occurred in the
travoprost-treated eyes compared to the latanoprost-trea-
ted eyes, with OSDI surveys also showing a trend toward
more dryness and irritation symptoms in the travoprost
eyes. There were no differences in tear breakup times
(TBUT), intraocular pressure, visual acuity or Schirmer
testing between the two groups [23]. In an open-label,
prospective study of patients (n = 20) with a baseline
TBUT of less than 6 seconds, significant increases in
mean TBUT and decreases in mean OSDI scores and
corneal staining were reported 8 weeks after switching
from latanoprost to travoprost with sofZia [21].
In contrast, in a prospective, double-masked, rando-
mized comparative study of 54 subjects, there were no
significant differences between latanoprost and travo-
prost with sofZia with respect to reported discomfort
scores following a single instillation of either agent [22].
In a small, prospective, observational cohort study with
masked examiners supported by Merck [24], patients
with glaucoma or ocular hypertension (naive to treat-
ment, n = 10; previously on latanoprost, n = 8) were
instructed to use latanoprost in the right eye and travo-
prost with sofZia in the left eye. There was statistically
significantly less conjunctival hyperemia in eyes treated
with latanoprost (both in the naive and previously trea-
ted patients) and in corneal staining in eyes previously
treated with latanoprost but no statistical difference in
TBUT, change in intraocular pressure from baseline, or
impression cytology between the treatment groups [24].
None of these studies specifically assessed the incidence
of ocular infections or rates of bottle contamination;
additional studies are warranted.
Patients receiving ocular hypotensive medications are
reported to have a high prevalence of OSD, with 59% of
patients reporting OSDI symptoms in at least one eye;
Schirmer testing was abnormal in 61% of patients and
TBUT was decreased in 78% of patients [25]. After
adjustment for age and sex, factors considered to influ-
ence the prevalence of OSD, multivariate logistic regres-
sion found that the use of BAK-containing agents was
associated with a two-fold increase risk of lissamine
green staining in the 22% of patients with positive
results (none had severe staining based on a scale of 0
to I, normal; II to III, mild to moderate; and IV to V,
severe). These rates are higher than those reported in
population-based studies, which likely reflects the fact
that some of these patients may have been referred due
to OSD symptoms or may have been treated with multi-
ple preservative-containing eye drops [25]. This hypoth-
esis is consistent with the results of a retrospective
analysis of three large prescription databases sponsored
by Pfizer [26]. Patients newly treated with latanoprost or
travoprost with sofZia and without a diagnosis of dry
eye or ocular infection in the prior 6 months had no
significant differences in the rates of dry eye or ocular
infections (identified by International Classification of
Diseases, Ninth Revision, Clinical Manifestation code or
by prescription for cyclosporine ophthalmic emulsion or
ocular antibiotics) at 1 year [26].
Of importance in considering the findings of the present
study, patients with OSD have an increased risk of micro-
bial keratitis [27-29], with OSD found to be a predisposing
factor in 21% of cases of bacterial keratitis in one study
[27] and in 15% of case in another study [28]. Staphylococ-
cus species were found to be the most commonly isolated
organisms in OSD-associated bacterial keratitis [27,29].
Moreover, a history of OSD was found to be significantly
associated with a “very poor” visual outcome following
bacterial keratitis [23]. Thus, the failure of travoprost to
satisfy even EP-B requirements due to the limited effec-
tiveness against Staphylococcus aureus at 24 hours raises
concerns about the adequacy of its preservation.
To date, in clinical usage and in observational studies,
the findings are mixed with regard to ocular tolerability
and may depend upon the study design. While some
switch studies found improvements in tolerability when
switching from bimatoprost/latanoprost to travoprost
with sofZia [20,21], one study found increases in corneal
staining and irritation when switching from travoprost
with sofZia to latanoprost [23]. Still, in the large, retro-
spective study sponsored by Pfizer [26], there were no
significant differences in dry eye or infection between
patients receiving latanoprost versus travoprost with sof-
Zia. The randomized, masked, clinical registration study
sponsored by Alcon comparing travoprost with BAK to
travoprost with sofZia found no differences in adverse
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benefits of BAK-free or other alternative preservative
systems in terms of ocular tolerability remain to be
clearly established.
Conclusion
The rapid microbial reduction, along with the complete
reduction of all microbial challenges with latanoprost
ophthalmic solution with BAK, demonstrates that its
antimicrobial activity exceeds that of travoprost with the
sofZia preservative system and will afford greater protec-
tion against contamination and subsequent exposure to
microbial insults during normal use. This antimicrobial
activity is reassuring in the typical patient with glau-
coma who is predisposed to OSD.
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